Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Acquisitions & Divestments (2023 - 2025)

CG Oncology (CGON) has disclosed Change in Acquisitions & Divestments for 3 consecutive years, with $222.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments fell 2.6% year-over-year to $222.2 million, compared with a TTM value of $844.1 million through Dec 2025, up 13.24%, and an annual FY2025 reading of $844.1 million, up 13.24% over the prior year.
  • Change in Acquisitions & Divestments was $222.2 million for Q4 2025 at CG Oncology, down from $251.4 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $251.4 million in Q3 2025 and bottomed at $30.7 million in Q3 2023.
  • Average Change in Acquisitions & Divestments over 3 years is $185.0 million, with a median of $200.7 million recorded in 2024.
  • The sharpest move saw Change in Acquisitions & Divestments skyrocketed 556.36% in 2024, then fell 2.6% in 2025.
  • Year by year, Change in Acquisitions & Divestments stood at $230.0 million in 2023, then dropped by 0.81% to $228.2 million in 2024, then fell by 2.6% to $222.2 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for CGON at $222.2 million in Q4 2025, $251.4 million in Q3 2025, and $170.4 million in Q2 2025.